GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Anupam Rasayan India Ltd

Anupam Rasayan India: Q1 FY27 Consolidated Revenue Up 36% to ₹6,675 Mn

RESULTS ▲ Positive Development LOW RISK
📅 Filed on BSE: 14 Aug 2026, 12:21 PM IST  ·  BSE ID: 707d555d-bafe-4ca3-8167-27d74c90d85e
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's latest quarterly financial report shows strong consolidated sales growth and new product launches.
🤖 AI Summary
  • Anupam Rasayan India reported consolidated total revenue of ₹6,675 Mn for Q1 FY27, a 36% YoY growth.
  • Consolidated Profit After Tax (PAT) for Q1 FY27 stood at ₹512 Mn, increasing by 6% YoY.
  • The company commercialized 3 new products in Q1 FY27, expanding its portfolio to over 125 products.
  • Anupam Rasayan became the world's first company to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry.
  • A Letter of Intent (LoI) was signed with BASQUEVOLT S.A. for a potential $300 million revenue opportunity over 10 years.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Consolidated Total Income Q1 FY27
₹6,675 Mn
36%
Consolidated EBITDA Q1 FY27
₹1,749 Mn
35%
Consolidated Profit After Tax Q1 FY27
₹512 Mn
6%
Standalone Total Income Q1 FY27
₹3,349 Mn
4%
Standalone Profit After Tax Q1 FY27
₹320 Mn
8%
🏢 How This Affects the Company
📈
Business Impact
Consolidated revenue growth of 36% YoY indicates increased sales volume and new product commercialization in pharmaceutical and performance material segments. The LoI with BASQUEVOLT S.A. and the ETFA commercialization strengthen the company's innovation and long-term revenue pipeline.
💰
Financial Impact
Consolidated EBITDA grew by 35% YoY to ₹1,749 Mn, with margins maintained at 26%. Consolidated PAT increased 6% YoY to ₹512 Mn, while PAT margin decreased to 8% from 10% in Q1 FY26.
⚙️
Operational Impact
Commercialization of ETFA using flow chemistry demonstrates enhanced process capabilities. The progress on Bliss GVS Pharma acquisition and completed Jayhawk Fine Chemicals acquisition expands manufacturing footprint and CDMO capabilities.
👥 What This Means For Shareholders
✅
Action Required
No action required from shareholders based on this investor presentation filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with Q1 FY27 consolidated EPS at ₹3.40 and standalone EPS at ₹2.81.
🔍
Management Signal
Management is signaling a focus on strategic growth through new product development, technological advancements (ETFA), and inorganic expansion via acquisitions.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Completion of Bliss GVS Pharma acquisition and its integration.
Progress on the BASQUEVOLT S.A. LoI and commercialization in FY27.
Q2 FY27 financial results to assess sustained growth trajectory.
LOW RISK The filing reports strong financial results and strategic initiatives without indicating new significant risks.
💡 Investor Takeaway
Anupam Rasayan India reported Q1 FY27 consolidated total revenue of ₹6,675 Mn, a 36% YoY increase. Consolidated EBITDA rose 35% YoY to ₹1,749 Mn. Consolidated Profit After Tax increased 6% YoY to ₹512 Mn. The company also confirmed 3 new product commercializations and a $300 million LoI.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Total Revenue grew 36% YoY to ₹6,675 Mn in Q1 FY27, driven by new product commercialization and demand.
  • Consolidated EBITDA increased 35% YoY to ₹1,749 Mn, with margins maintained at 26% in Q1 FY27.

⚠️ Concerns

  • Consolidated Profit After Tax growth of 6% YoY to ₹512 Mn in Q1 FY27 was lower than revenue and EBITDA growth.
  • Consolidated PAT Margin decreased to 8% in Q1 FY27 from 10% in Q1 FY26.
📅 Company Track Record
Anupam Rasayan India's Q1 FY27 consolidated revenue of ₹6,675 Mn represents a 36% YoY growth, building on the FY26 consolidated revenue of ₹23,836 Mn. The company previously achieved ~9x consolidated revenue growth from FY14 to FY26. A prior press release on the same day stated Q1 FY27 consolidated revenue was up 36% YoY to Rs 6,675 Mn, PAT up 6% to Rs 512 Mn.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Anupam Rasayan India's consolidated total revenue for Q1 FY27?
Anupam Rasayan India reported consolidated total revenue of ₹6,675 Mn for the quarter ended June 30, 2026, marking a 36% YoY growth.
What was Anupam Rasayan India's consolidated Profit After Tax (PAT) in Q1 FY27?
The consolidated Profit After Tax for Anupam Rasayan India in Q1 FY27 was ₹512 Mn, which is a 6% increase compared to Q1 FY26.
How many new products did Anupam Rasayan India commercialize in Q1 FY27?
Anupam Rasayan India commercialized 3 new products in Q1 FY27, increasing its total product portfolio to over 125.
What is the potential revenue opportunity from the LoI with BASQUEVOLT S.A. for Anupam Rasayan India?
The Letter of Intent with BASQUEVOLT S.A. creates a potential revenue opportunity of up to US$300 million for Anupam Rasayan India over a 10-year period.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.